EP 1425391 A1 20040609 - THERAPEUTIC VACCINATION METHOD, MUTATED PEPTIDES OF HIV REVERSE TRANSCRIPTASE AND THEIR USE FOR VACCINATION AND DIAGNOSTIC PURPOSES
Title (en)
THERAPEUTIC VACCINATION METHOD, MUTATED PEPTIDES OF HIV REVERSE TRANSCRIPTASE AND THEIR USE FOR VACCINATION AND DIAGNOSTIC PURPOSES
Title (de)
VERFAHREN ZUR THERAPEUTISCHEN IMPFUNG, MUTIERTE PEPTIDDERIVATE DER REVERSEN TRANSKRIPTASE DES HIV UND IHRE NUTZUNG FÜR IMPFUNG UND DIAGNOSE
Title (fr)
PROCEDE DE VACCINATION THERAPEUTIQUE, PEPTIDES MUTES DE LA TRANSCRIPTASE INVERSE DE VIH ET LEUR UTILISATION A DES FINS DE VACCINATION ET EN DIAGNOSTIC
Publication
Application
Priority
FR 0102872 W 20010914
Abstract (en)
[origin: WO03025166A1] The invention concerns treatment of infectious and tumoral pathologies comprising a anti-infective and/or anti-tumoral chemotherapeutic treatment phase inducing resistance mutations and a therapeutic vaccination phase directed against said resistance mutations and the agents used in said treatment. More particularly, the invention concerns peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence and comprising at least a mutation with respect to said wild sequence of said enzyme, mutation induced in response to treatments by nucleoside and non-nucleoside analogues of the HIV reverse transcriptase. The invention also concerns a pharmaceutical composition or vaccine based on said peptides, for inducing an immune response specific of said mutated sequences and for enhancing or prolonging the efficiency of treatments with nucleoside or non-nucleoside analogues of the HIV reverse transcriptase. The invention further concerns epitopes derived from said peptide sequences to evaluate the specific immune response following the vaccine injection.
IPC 1-7
IPC 8 full level
A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 48/00 (2006.01); A61P 31/00 (2006.01); A61P 31/18 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C12N 9/12 (2006.01); C12Q 1/02 (2006.01)
CPC (source: EP US)
A61P 31/00 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 35/00 (2018.01 - EP); C12N 9/1276 (2013.01 - EP US); A61K 39/00 (2013.01 - EP US); C12N 2799/021 (2013.01 - EP US)
Citation (search report)
- [Y] MELLORS J W ET AL: "MUTATIONS IN HIV-1 REVERSE TRANSCRIPTASE AND PROTEASE ASSOCIATED WITH DRUG RESISTANCE", INTERNATIONAL ANTIVIRAL NEWS, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 3, 1995, pages 8 - 13, XP000614717, ISSN: 0965-2310
- [Y] MASQUELIER B ET AL: "GENOTYPIC AND PHENOTYPIC RESISTANCE PATTERNS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 VARIANTS WITH INSERTIONS OR DELETIONSIN THE REVERSE TRANSCRIPTASE (RT): MULTICENTER STUDY OF PATIENTS TREATED WITH RT INHIBITORS", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 45, no. 6, June 2001 (2001-06-01), pages 1836 - 1842, XP001016398, ISSN: 0066-4804
- [A] HAAS ET AL: "Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease", AIDS, LONDON, GB, vol. 12, no. 12, 1998, pages 1427 - 1436, XP002117622, ISSN: 0269-9370
- [PA] MILLER V ET AL: "MUTATIONAL PATTERNS IN THE HIV GENOME AND CROSS-RESISTANCE FOLLOWING NUCLEOSIDE AND NUCLEOTIDE ANALOGUE DRUG EXPOSURE", ANTIVIRAL THERAPY, MTM PUBLICATIONS, LONDON, GB, vol. 6, no. SUPPL 3, 2001, pages 25 - 44, XP001146546, ISSN: 1359-6535
- See also references of WO 03025166A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 03025166 A1 20030327; CA 2460377 A1 20030314; EP 1425391 A1 20040609; JP 2005503418 A 20050203; US 2005074463 A1 20050407
DOCDB simple family (application)
FR 0102872 W 20010914; CA 2460377 A 20010914; EP 01969902 A 20010914; JP 2003529940 A 20010914; US 48912304 A 20041022